Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Verdure acquisition

This article was originally published in The Tan Sheet

Executive Summary

Verdure Sciences moves aggressively in its plan to focus on research and development of bionutritionals by acquiring Geni Herb's patent-pending pomegranate extract Pomella and other branded botanical ingredients including Tinofend, Bacognize, Wokvel and Calzbone. Terms of the deal were not disclosed. The Indianapolis, Ind.-based firm, which also has a facility in Heilbronn, Germany, says it expects the transaction to make it a leading U.S. marketer of nutritional ingredients. The Geni brands also are marketed in Europe and Southeast Asia. Noblesville, Ind.-based Geni, which agreed to the Verdure deal in April 2006, also has moved the marketing and distribution of its ayurvedic botanicals to Stauber Performance Ingredients in an agreement made in September...

You may also be interested in...

PomElla Lawsuit Could Squeeze Verdure’s Play In Pomegranate Market

Verdure Sciences' planned growth in the bionutrional arena could be slowed by a lawsuit claiming that a California entrepreneur developed the pomegranate extract product that Verdure acquired recently from Geni Herbs

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts